Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: prognostic effect of proton pump inhibitor use
In this retrospective analysis of 359 patients, the co-administration of PPIs with CDK4/6i was associated with significantly shorter PFS and OS. Clinicians should be cautious when prescribing PPIs to patients receiving CDK4/6i therapy due to the potential for adverse effects on treatment outcomes.
Authors
- Pei‐Ju Lien (ORCID: https://orcid.org/0000-0003-4644-1533)
- Yen-Jen Chen
- Jiun‐I Lai (ORCID: https://orcid.org/0000-0002-8233-5466)
- Bo-Fang Chen (ORCID: https://orcid.org/0000-0002-4053-5232)
- Ling‐Ming Tseng (ORCID: https://orcid.org/0000-0002-4648-6646)
- Chin-Jung Feng
- Han-Fang Cheng
- Chi‐Cheng Huang (ORCID: https://orcid.org/0000-0003-4378-4776)
- Yen‐Shu Lin
- Ta-Chung Chao
- Yi-Fang Tsai
- Chun-Yu Liu
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- National Taipei University of Nursing and Health Science (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1093/oncolo/oyaf268
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00